DUKE Robotics Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DUKE Robotics Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $377.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $108.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $300.0K | Mar 20, 2025 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 24, 2023 |
| FY2020 | Dec 31, 2019 | $112.0K | Mar 30, 2021 |
| FY2018 | Dec 31, 2017 | $5.0K | Mar 29, 2019 |
| FY2016 | Dec 31, 2015 | $26.0K | Mar 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $27.0K | Mar 20, 2025 |
| FY2021 | Dec 31, 2021 | $500.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $7.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($5.1K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $259 | Mar 29, 2019 |
| FY2016 | Dec 31, 2015 | $16.3K | Mar 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.24M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($985.0K) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($726.0K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.10M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($888.0K) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.37M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($1.11M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($142.3K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($149.1K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($299.2K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.21M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.03M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($802.0K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($1.12M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($442.0K) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.31M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($1.03M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($105.7K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($109.6K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($268.3K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $157.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $20.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.0K | Mar 24, 2023 |
| FY2020 | Dec 31, 2019 | $75.0K | Mar 30, 2021 |
| FY2017 | Dec 31, 2016 | $4.7K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $508 | Mar 28, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.31M | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | $961.0K | Mar 30, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($811.0K) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($918.0K) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($548.0K) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($672.0K) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($234.0K) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($849.0K) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($138.0K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($60.4K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($82.7K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($180.1K) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $77.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $18.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $35.0K | Mar 15, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.25M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.63M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.48M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.99M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.61M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $136.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $63.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $26.3K | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $34.3K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $36.1K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $776.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $671.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $566.0K | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $508.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.99M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.82M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $773.8K | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $639.4K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $512.3K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $851.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.81M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.43M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $3.10M | Mar 15, 2024 |
| FY2021 | Dec 31, 2020 | ($1.85M) | Mar 7, 2022 |
| FY2021 | Dec 31, 2019 | ($1.76M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | ($1.19M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($605.1K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2016 | ($476.2K) | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.40M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($11.16M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($9.95M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($9.02M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($6.02M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($5.13M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($3.76M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($890.6K) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($748.3K) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($599.2K) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $750.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.26M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.28M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.85M | Mar 15, 2024 |
| FY2021 | Dec 31, 2021 | $3.56M | Mar 7, 2022 |
| FY2021 | Dec 31, 2020 | $105.0K | Mar 7, 2022 |
| FY2021 | Dec 31, 2019 | $23.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $190.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $343 | Apr 13, 2020 |
| FY2017 | Dec 31, 2015 | $14.1K | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 24, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 24, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.17M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 2.17M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 54.22M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 54.22M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 54.02M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 40.08M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 25.13M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 1.17M | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | 1.17M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 1.17M | Mar 29, 2018 |